Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Peter Habenberger"'
Autor:
Patricia Johansson, Laura Dierichs, Ludger Klein-Hitpass, Anke K. Bergmann, Michael Möllmann, Sascha Menninger, Peter Habenberger, Bert Klebl, Jens T. Siveke, Ulrich Dührsen, Axel Choidas, Jan Dürig
Publikováno v:
Therapeutic Advances in Hematology, Vol 11 (2020)
T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by chemotherapy resistance and a median survival of less than 2 years. Here, we investigated the pharmacological effects of the novel highly specific cyclin-dependent ki
Externí odkaz:
https://doaj.org/article/dbaad95c53fa476da2bd0fedf8b2e735
Autor:
Johannes Brägelmann, Marcel A. Dammert, Felix Dietlein, Johannes M. Heuckmann, Axel Choidas, Stefanie Böhm, André Richters, Debjit Basu, Verena Tischler, Carina Lorenz, Peter Habenberger, Zhizhou Fang, Sandra Ortiz-Cuaran, Frauke Leenders, Jan Eickhoff, Uwe Koch, Matthäus Getlik, Martin Termathe, Muhammad Sallouh, Zoltán Greff, Zoltán Varga, Hyatt Balke-Want, Christopher A. French, Martin Peifer, H. Christian Reinhardt, László Örfi, György Kéri, Sascha Ansén, Lukas C. Heukamp, Reinhard Büttner, Daniel Rauh, Bert M. Klebl, Roman K. Thomas, Martin L. Sos
Publikováno v:
Cell Reports, Vol 20, Iss 12, Pp 2833-2845 (2017)
Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midline carcin
Externí odkaz:
https://doaj.org/article/65260813004b4d5e8d198b9f59d2baa6
Autor:
Thomas Ihle Aarhus, Frithjof Bjørnstad, Camilla Wolowczyk, Kristin Uhlving Larsen, Line Rognstad, Trygve Leithaug, Anke Unger, Peter Habenberger, Alexander Wolf, Geir Bjørkøy, Clare Pridans, Jan Eickhoff, Bert Klebl, Bård H. Hoff, Eirik Sundby
Publikováno v:
Aarhus, T I, Bjørnstad, F, Wolowczyk, C, Larsen, K U, Rognstad, L, Leithaug, T, Unger, A, Habenberger, P, Wolf, A, Bjørkøy, G, Pridans, C, Eickhoff, J, Klebl, B, Hoff, B H & Sundby, E 2023, ' Synthesis and Development of Highly Selective Pyrrolo[2,3-d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form ', Journal of Medicinal Chemistry, vol. 66, no. 10, pp. 6959-6980 . https://doi.org/10.1021/acs.jmedchem.3c00428
Colony-stimulating factor-1 receptor (CSF1R) is a receptor tyrosine kinase that controls the differentiation and maintenance of most tissue-resident macrophages, and the inhibition of CSF1R has been suggested as a possible therapy for a range of huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eadb975b45033dbb1fd91897a1eaf34
https://hdl.handle.net/20.500.11820/1b3ebb9b-cf94-456a-948e-bbbf0e0e8792
https://hdl.handle.net/20.500.11820/1b3ebb9b-cf94-456a-948e-bbbf0e0e8792
Autor:
Thomas I. Aarhus, Vilde Teksum, Anke Unger, Peter Habenberger, Alexander Wolf, Jan Eickhoff, Bert Klebl, Camilla Wolowczyk, Geir Bjørkøy, Eirik Sundby, Bård H. Hoff
Publikováno v:
European Journal of Organic Chemistry. 26
Publikováno v:
Cancers 14(18), 4386 (2022). doi:10.3390/cancers14184386
Cancers 14(18), 4386 (2022). doi:10.3390/cancers14184386
Published by MDPI, Basel
Published by MDPI, Basel
Identification of an (−)-englerin A analogue, which antagonizes (−)-englerin A at TRPC1/4/5 channels
Autor:
Mathias Christmann, Peter Nussbaumer, Herbert Waldmann, Klaus Dinkel, Bert Klebl, David J. Beech, Peter Habenberger, Hussein N. Rubaiy, Axel Choidas, Tobias Seitz, Sven Hahn
Publikováno v:
British Journal of Pharmacology. 175:830-839
Background and Purpose: (−)‐Englerin A (EA) is a potent cytotoxic agent against renal carcinoma cells. It achieves its effects by activation of transient receptor potential canonical (TRPC)4/TRPC1 heteromeric channels. It is also an agonist at ch
Autor:
Bert Klebl, Hans R. Schöler, Herbert Waldmann, Matthias Baumann, Gisbert Schneider, Jared Sterneckert, Lea Kremer, Susanne Kordes, Peter Habenberger, Carsten Schultz-Fademrecht, Slava Ziegler, Axel Choidas
Publikováno v:
Angewandte Chemie International Edition. 56:13021-13025
Cell-based assays enable monitoring of small-molecule bioactivity in a target-agnostic manner and help uncover new biological mechanisms. Subsequent identification and validation of the small-molecule targets, typically employing proteomics technique
Autor:
Felix Dietlein, Roman K. Thomas, Martin Peifer, Daniel Rauh, Zoltán Varga, Johannes M. Heuckmann, Axel Choidas, Johannes Brägelmann, Jan Eickhoff, Carina Lorenz, Hyatt Balke-Want, György Kéri, Zhizhou Fang, Stefanie Böhm, Zoltán Greff, Muhammad Sallouh, Martin Termathe, Reinhard Büttner, Debjit Basu, Christopher A. French, Uwe Koch, Frauke Leenders, André Richters, Martin L. Sos, Verena Tischler, Bert Klebl, Sascha Ansén, Peter Habenberger, Laszlo Orfi, Matthäus Getlik, Sandra Ortiz-Cuaran, Marcel A. Dammert, Lukas C. Heukamp, H. Christian Reinhardt
Publikováno v:
Cell Reports
Cell Reports, Vol 20, Iss 12, Pp 2833-2845 (2017)
Cell Reports, Vol 20, Iss 12, Pp 2833-2845 (2017)
Summary Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midlin
Autor:
Peter Nussbaumer, Jan Eickhoff, Gabriel Sollberger, Axel Choidas, Arturo Zychlinsky, Renate Krüger, Garth L. Burn, Peter Habenberger, Sascha Menninger, Raffaella Di Lucrezia, Bert Klebl, Alf Herzig, Susanne Kordes
Publikováno v:
Science Immunology. 3
The death of a cell is an inevitable part of its biology. During homeostasis, most cells die through apoptosis. If homeostasis is disturbed, cell death can switch to proinflammatory forms of death, such as necroptosis, pyroptosis, or NETosis. We demo
Autor:
Bert Klebl, Slava Ziegler, Stephanie A. Ketcham, Axel Choidas, Hans R. Schöler, Matthias Baumann, Michael Glatza, Ting-Yu Yeh, Lydia Reinhardt, Herbert Waldmann, Jared Sterneckert, Peter Reinhardt, Philipp Küchler, Masin Abo-Rady, Gunther Zischinsky, Swaran Nandini, Peter Habenberger, Susanne Höing, Stephen J. King, Trina A. Schroer, Mia-Lisa Zischinsky, Hannes C.A. Drexler, Lea Kremer, Nancy E. Martinez, Aaron P. Ledray, Peter Nussbaumer
Publikováno v:
Cell Chem Biol
Summary Aberrant hedgehog (Hh) signaling contributes to the pathogenesis of multiple cancers. Available inhibitors target Smoothened (Smo), which can acquire mutations causing drug resistance. Thus, compounds that inhibit Hh signaling downstream of S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee2b34bf7961e88796ba78e05ec756a
https://europepmc.org/articles/PMC8543760/
https://europepmc.org/articles/PMC8543760/